| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3838 | Nvp-acq090 | Novel potent and selective antagonist of somatostatin receptor subtype SST(3) |
|
| DCC3839 | Nvp-aht202 | Novel BCR-ABL Kinase Inhibitor |
|
| DCC3840 | Nvp-bhs345 | Novel dual inhibitor of TORC1 and TORC2 |
|
| DCC3841 | Nvp-bvb808 | Novel potent Jak2 type 1 inhibitor |
|
| DCC3842 | Nvp-cfc218 | Novel potent and selective p53-HDM2 inhibitor |
|
| DCC3843 | Nvp-dpp728 | Potent, orally active dipeptidyl peptidase (DPP)-IV inhibitor |
|
| DCC3844 | Nvp-lbm415 | Novel peptide deformylase (PDF) inhibitor; Antibacterial |
|
| DCC3845 | Nvp-qab205 | Novel Syk inhibitor |
|
| DCC3846 | Nvp-saa164 | Novel nonpeptide bradykinin B1 receptor antagonist |
|
| DCC3847 | Nvp-sra880 | The first non-peptide somatostatin sst(1) receptor antagonist |
|
| DCC3848 | Nvp-tac544 | Novel focal adhesion kinase (FAK) inhibitor, potently blocking kinase activity of FAK along with Aurora A, activated Cdc42-associated kinase 1 (ACK1), Met, insulin receptor (IR), TrkA, and IGF-1R |
|
| DCC3849 | Nvp-vid400 | Specific inhibitor of the 25-hydroxyvitamin D(3)-24-hydroxylase (24-hydroxylase) |
|
| DCC3850 | Nvp-xaa228 | Novel potent PKCθ inhibitor |
|
| DCC3851 | Nvs-bet-2 | Novel selective bromodomain and extra-terminal domain (BET) protein family inhibitor (BETi ), inducing an ‘activated’ keratinocyte transcriptional profile with reversal of chronic wound biomarkers in human skin ex vivo |
|
| DCC3852 | Nvs-mllt-1 | Novel Potent and Selective inhibitor of YEATS proteins |
|
| DCC3853 | Nvs-pak1-c | Negative control for NVS-PAK1-1 (8778) |
|
| DCC3854 | Nvs-sm2 | Potent, orally active, small-molecule enhancer of SMN2 splicing, binding to and stabilizing the U1 snRNP:5′ss RNA complex |
|
| DCC3855 | Nvx-108 | Exceptional oxygen transporter, increasing brain tissue oxygen tension (PbtO2) when administered soon after traumatic brain injury (TBI) |
|
| DCC3856 | Nw-1772 | Highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor |
|
| DCC3857 | Nxd30001 | Novel potent Hsp90 inhibitor, inducing tumor regression in a genetically engineered mouse model of glioblastoma multiforme |
|
| DCC3858 | nxn-188 | Selective nNOS inhibitor and a5-HT1B/1D receptor agonist |
|
| DCC3859 | Nybomycin | Anti-microbial agent against Mycobacterium smegmatis and Mycobacterium bovis BCG, binding to DNA and inducing a unique morphological change to mycobacterial bacilli leading the bacterial cell death |
|
| DCC3860 | Ny-eso-1 | Cancer-testis antigen (CTA) with re-expression in numerous cancer types, eliciting spontaneous humoral and cellular immune responses, restricting expression pattern, being a good candidate target for cancer immunotherapy |
|
| DCC3861 | Nystatin-3 | Novel water-soluble nystatin derivative, being fully water-soluble (up to 1 g/mL) with the same potency of Nystatin but with 13.5 times lower toxicity |
|
| DCC3862 | O-1302 | Potent CB1 receptor antagonist |
|
| DCC3863 | O-1663 | Novel inhibitor of advanced stages of breast cancer, targeting multiple cannabinoid anti-tumour pathways |
|
| DCC3864 | o-1918 | Novel GPR18 antagonist, blocking the effects of Abn-CBD and NAGly. |
|
| DCC3865 | Oa-adp-hpd | Poly(ADP-Ribose) Glycohydrolase (PARG) inhibitor |
|
| DCC3866 | Oat-1441 | Novel Selective and Orally Bioavailable Inhibitor of Human Acidic Mammalian Chitinase (hAMCase) |
|
| DCC3867 | O-bn-thaz Fumarate | Potent agonist of the human 5-HT2A and 5-HT2C receptors |
|
